In order to further improve the standardized diagnosis and treatment of refractory cancer pain in primary medical institutions and benefit the majority of cancer pain patients, the Sichuan Continuing Medical Education Project "Standardized Diagnosis and Treatment Training Course for Refractory Cancer Pain" is jointly sponsored by Chengdu High-tech Medical Association and Chengdu First People's Hospital, undertaken by the Second Oncology Special Committee and the Youth Committee of the Oncology Special Committee of Chengdu High-tech Medical Association, and jointly co-organized by Chengdu Traditional Chinese Medicine Oncology Professional Medical Quality Control Center and Chengdu High-tech Zone Tumor Disease Quality Control Sub-Center The training course on standardized diagnosis and treatment of cancer pain led by the spirit of Bethune was successfully held in Rongzhou on August 24, 2025.

     The training course focuses on the frontiers of cancer pain diagnosis and treatment, and the content is detailed and rich. The experts at the meeting not only shared the latest trends, concepts and developments in the diagnosis and treatment of gastrointestinal tumors, but also focused on the core issues of refractory cancer pain, and discussed in depth the comprehensive and multi-dimensional content of accurate assessment of cancer pain, drug treatment strategies, interventional treatment techniques, multidisciplinary collaboration (MDT) model, humanistic care and patient psychological support through keynote speeches, theoretical lectures, case analysis, interactive discussions and other forms.

        In addition, this conference also integrated the live broadcast of health science popularization, focusing on "cancer pain in the high-tech zone under the guidance of the spirit of Bethune - the direction of our struggle", dispelling the cognitive fog of cancer pain management for the public, and deeply cultivating discipline construction in the high-tech zone under the guidance of the spirit of Bethune, helping to improve the public's scientific cognition and precise treatment level of cancer pain.